Objective: Breast cancer control in Ghana is characterised by low awareness, late-stage treatment and poor survival. In settings with severely constrained health resources, there is a need to spend money wisely. To achieve this and to guide policy makers in their selection of interventions, this study systematically compares costs and effects of breast cancer control interventions in Ghana.
Methods: We used a mathematical model to estimate costs and health effects of breast cancer interventions in Ghana from the healthcare perspective. Analyses were based on the WHO-CHOICE method, with health effects expressed in disability-adjusted life years (DALYs), costs in 2009 US dollars (US$) and cost-effectiveness ratios (CERs) in US$ per DALY averted. Analyses were based on local demographic, epidemiological and economic data, to the extent these data were available.
Results: Biennial screening by clinical breast examination (CBE) of women aged 40-69 years, in combination with treatment of all stages, seems the most cost-effective intervention (costing $1299 per DALY averted). The intervention is also economically attractive according to international standards on cost-effectiveness. Mass media awareness raising (MAR) is the second best option (costing $1364 per DALY averted). Mammography screening of women of aged 40-69 years (costing $12,908 per DALY averted) cannot be considered cost-effective.
Conclusions: Both CBE screening and MAR seem economically attractive interventions. Given the uncertainty about the effectiveness of these interventions, only their phased introduction, carefully monitored and evaluated, is warranted. Moreover, their implementation is only meaningful if the capacity of basic cancer diagnostic, referral and treatment and possibly palliative services is simultaneously improved.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-3156.2012.03021.x | DOI Listing |
Adv Sci (Weinh)
January 2025
Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, P. R. China.
Tumor heterogeneity remains a formidable obstacle in targeted cancer therapy, often leading to suboptimal treatment outcomes. This study presents an innovative approach that harnesses controlled inflammation to guide neutrophil-mediated drug delivery, effectively overcoming the limitations imposed by tumor heterogeneity. By inducing localized inflammation within tumors using lipopolysaccharide, it significantly amplify the recruitment of drug-laden neutrophils to tumor sites, irrespective of specific tumor markers.
View Article and Find Full Text PDFInt J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Cell Mol Biol (Noisy-le-grand)
January 2025
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Mitochondrial ribosomal protein S23 (MRPS23), encoded by a nuclear gene, is a well-known driver of proliferation in cancer. It participates in mitochondrial protein translation, and its expression association has been explored in many types of cancer. However, MRPS23 expression associations are rarely reported in breast cancer (BC).
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
January 2025
Istanbul University, Faculty of Science, Department of Biology, Istanbul, Türkiye.
In this study, the effects of histone deacetylase inhibitor CI-994 and nanotechnological drug liposomal cisplatin LipoPlatin on Luminal A breast cancer and triple-negative breast cancer were explored using agents alone and in combination. MCF-7 and MDA-MB-231 cell lines were used. Cell viability, and cell index values obtained from xCELLigence System, MI, BrdU LI and AI were evaluated in experiments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!